Purpose: The Coronavirus disease 2019 reminds us of the SARS outbreak in 2003, and up to date, corticosteroid is commonly administrated to severe patients with COVID-19. Osteonecrosis of the femoral head (ONFH) is a common disabling complication among convalescent SARS patients who received corticosteroid therapy. In China, a considerable number of convalescent SARS patients with steroid-associated ONFH had undergone conservative treatment by Traditional Chinese Medicine (TCM), and this study aims to evaluate the long-term results of a spleen-invigorating Huo-Gu Formula (HGF) therapy in these patients.
Introduction
The Coronavirus disease (COVID-19) outbreak in 2019 reminds us of the worldwide outbreak of severe acute respiratory syndrome (SARS) emerged in 2002 to 2003. Similarly, no specific therapy is available for the coronavirus 1 . It is estimated that corticosteroid therapy were administrated to 18% of COVID-19 patients, with a higher percentage among those with severe disease (44%) than nonsevere disease (13%) 2 . Osteonecrosis, pulmonary fibrosis, and depression are commonly seen among convalescent SARS patients. ONFH in SARS survivors could be attributed to the steroid since high cumulative doses of steroids were closely associated with the occurrence of osteonecrosis 3 .
Steroid-associated ONFH can progressively break down the underlying bone of the hip joint and thus induce severe premature osteoarthritis of the hip, which would further cause physical disability in these SARS survivors 4 .
To date, all treatment strategies currently available for pre-collapse steroid-associated ONFH, frequently named as hip-preserving treatments, are not able to completely stop the rapid progression to either the collapse of the femoral head or the hip osteoarthritis. A review of pertinent literature indicates that there is no better treatment than total hip arthroplasty (THA) for hips with a post-collapse course 5 .
However, patients should be carefully selected for THA due to limited implant lifespan and diverse operative complications.
Not all patients with steroid-associated ONFH have undergone operative treatments 4, 6 . Disappointingly, a meta-analysis published in 2019 had concluded that post-marketing drugs, including enoxaparin, statins, bisphosphonates, iloprost, and acetylsalicylic acid, were not recommendable for this disease 7 .
One of the reasons why these single-component drugs fail to take effect is that steroid-associated ONFH is a multifactorial disease with complex signal pathways involved 8 . This mechanism explains the fact that not all individuals who continue long-term steroid therapy develop steroid-associated ONFH. Chinese medicine may be a potential solution for steroid-associated ONFH, since it is based on network pharmacology through a network-target and multi-components mechanism 9 .
In China, quite a few ONFH patients are undergoing pharmacological treatments, especially treatment by Traditional Chinese Medicine (TCM) 4, 6, 10 . In 2012, "Chinese Experts' Consensus on the Diagnosis and Treatment of Osteonecrosis of the Femoral Head in Adults (2012)" recommended Chinese medicine as one of the pharmacological treatments for ONFH 11 . "Chinese Guideline for the Clinical Diagnosis and Treatment of Femoral Head Necrosis in Adults (2016)" were formulated based on evidence-based medicine 12 . Based on the 2016 version guideline, professional specialists, scholars, and orthopedist from Europe, Asia, America, and China jointly develop new guidelines for further standardized and effective clinical diagnosis and treatment of adults ONFH as "Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019)" 13 . Additionally, a meta-analysis that included 23 randomized controlled trials reported that Chinese medicine helped enhance the effect of core decompression surgery for ONFH 14 . However, the therapeutic outcomes of Chinese medicine treatment used alone are less investigated and reported, especially long-term follow-up studies are lacking.
Huo-Gu Formula (HGF) is a Chinese herbal medication that is commonly administrated for patients with ONFH in China. Abnormal lipid metabolism has been reported to be involved in the development of ONFH 15 , and the TCM theory believes that Phlegm-Dampness (Tan-Shi) pathogen is closely associated with the abnormal lipid metabolism 16 . The main TCM function of HGF is to help invigorate the Spleen(Pi) to clear Dampness, resolve Phlegm, and activate blood circulation. Previous animal testing had found an allopathic effect of HGF on preventing steroid-treated animals from developing steroid-associated ONFH 17, 18 . Interestingly, we found HGF also helps improve lipoprotein metabolism 17, 18 . Further experiments found that the ethyl acetate fraction of HGF helps inhibit the adipogenic differentiation of the bone marrow stromal cells 19 while the aqueous fraction of HGF promotes the osteogenic differentiation 20 . Here, we conducted a long-term retrospective study to evaluate the outcomes of HGF therapy for steroid-associated ONFH in convalescent SARS patients with an average of 14 years.
Participants and methods
This retrospective cohort study included 33 convalescent SARS patients (see Fig. 1 ) who were referred to Wangjing Hospital once confirmed the diagnosis of ONFH. In our hospital, a total of 45 convalescent SARS patients (94 hips) were treated by HGF therapy alone, but 12 patients were excluded from the present study. The clinical study had been conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Institutional Review Board of Wangjing Hospital. All patients consented to participate in this study. Inclusion criteria were convalescent SARS patients received steroid therapy, the case with bilateral hips affected, continuously received oral HGF treatment for at least 6 months once confirmed the diagnosis Among these 33 patients, there were nine males and 24 females with an average age of 42.52±8.26 years (range, 27 to 64 years, see Table 1 ). All patients are bilaterally affected (66 hips). The mean interval between the diagnosis of SARS and ONFH was 22.76±26.21 months (range, 6~127 months).
According to the ARCO classification, 10 hips were classified as stage (normal plain radiograph but with specific osteonecrosis findings on magnetic resonance imaging), 43 hips as stage (abnormal plain radiographs without collapse or a crescent sign), nine hips as stage III (abnormal plain radiographs with collapse or a crescent sign), and 4 hips as stage IV (abnormal plain radiographs with hip arthritis). Based on the lesion size determination criteria, there were 23 hips with a small lesion (<15% of femoral head involvement by necrotic volume), 12 hips with a medium lesion (15 to 30%) and 31 hips with a large lesion (>30%). According to the JIC classification criteria, there were 14 hips with a type A lesion (a lesion occupies the medial one-third or less of the weight-bearing portion), 16
hips with a type B lesion (a lesion occupies the medial two-thirds or less of the weight-bearing portion), 36 hips with type C (a lesion occupies more than the medial two-thirds of the weight-bearing portion).
All patients were followed up till November 2019, or they received THA. 
Huo-Gu Formula treatment
The TCM theory categorized corticosteroid as a drug-induced pathogen, which can act on every aspect of the human body and produces the Phlegm-Dampness (Tan-Shi) pathogen. Phlegm-Dampness blocking Meridian (Jing-Luo), which further induces Qi stagnation and Blood (Xue) stasis, is believed to be the pathological basis of corticosteroid-associated ONFH 22 . The Phlegm-Dampness pathogen affects mainly the lower part of the body. The hip (femoral head) is among the most susceptible joints to the Phlegm-Dampness pathogen. Once the Phlegm-Dampness pathogen affects the femoral head, the circulation of 'Qi' and 'Blood' along the Meridian around the hip is to be disturbed. When the Meridian branches passing through the femoral head can be blocked, the femoral head is to lose the nutrition of 'Qi' and 'Blood'.
Based on above TCM theories, the management strategy of TCM for the pathogen-induced disorders includes clearing Dampness, resolving Phlegm and activating blood circulation 11, 12 Table 2 12.0 g. HGF is generally taken twice a day before or between meals. The patients were also requested to restrict weight-bearing by using two crutches for one year. The electronic medical record was checked to make sure all participants had received homogeneous HGF treatment. Cinnamomi ramulus Guizhi 10
Atractylodis macrocephalae rhizoma Baizhu 12
Glycyrrhizae radix et rhizoma Gancao 3
Pinelliae rhizoma praeparatum Fabanxia 9
Radix salviae miltiorrhizae Dangshen 12
Angelicae sinensis radix Danggui 9
Chuanxiong rhizome Chuanxiong 10
Rehmanniae radix praeparatum Shudihuang
Paeonia radix rubra Chishao 9
Eupolyphaga steleophaga Tubiechong 9
Cervicornuscolla Lujiaojiao 12
Follow-up care
Routine outpatient follow-up took place monthly during HGF treatment, and every year after that.
Patients were requested to return to our clinics if they developed relapsing groin pain or other adverse reactions related to HGF treatment. All patients were evaluated by radiographs, CT scanning, and MRI at their routine clinic visits. Clinical information was also recorded by interviews and physical examinations.
Endpoint outcome assessment
The most recent follow-up investigation took place in November 2019. Every patient was invited to complete a questionnaire designed largely based on the Harris Hip Score (HHS, see Table 3 ) 23 , COS for ONFH-Walking function index 24 . The overall HHS can be divided into pain index and physical function index. The HHS-pain index classified the severity of pain by six grades, and the HHS-physical function index majorly includes measures of the ability of daily living (see Table 3 ). Three orthopedic surgeons who specialized in hip arthritis and were not involved in the present study were invited to evaluate the images. Each decision was made by consensus among the three surgeons. The collapse of the femoral head was defined as a fine radiolucent subchondral fracture line or a depression of articular surface. The degree of hip osteoarthritis was measured according to the Kellgren-Lawrence Classification (K-L classification) 25 . 
Statistical Analysis
With the THA as the endpoint, the mean survival time for all studied hip was calculated using the Kaplan-Meier method. The differences in the survival distributions between patient groups with different ARCO stages were tested with the log-rank test. Since the HHS is separated into pain index and physical function index, these sub-indexes were also analyzed and compared. As lately occurred groin pain in patients with ONFH are commonly ascribed to ONFH-induced osteoarthritis, we also analyzed the correlation between degrees of pain and degrees of osteoarthritis by Kendall's Tau-b test.
The correlation analysis between degrees of pain and degrees of walking function, as well as the correlation between degrees of osteoarthritis and degrees of walking function, were conducted by the same method. SPSS software (version 19.0; SPSS Inc, Chicago, IL) was used in all data processing.
Results
As of November 2019, all 33 patients provided complete data on the outcome measures at the final follow-up. The mean follow-up period was 14.88±2.25years (range, 6.25 to 16.83 years).
Therapeutic outcome
A total of five patients were converted to THA due to severe hip osteoarthritis (K-L Grade 4). With the hip replacement as the endpoint, the mean hip survival time without collapse was 15.95 years (95%CI:
15.25 to 16.71 years, see Fig.2A ). The hip survival duration largely depended on clinical stages. The conversion rate to THA of patients with ARCO stage was 75.00%, while the rate of hips with ARCO stage I to III was 0.03% in total. A significant difference in hip survival duration was observed between the subgroups divided by ARCO classification (p <0.001, by the log-rank test, see Fig. 2B ).
Harris hip score Fig. 2 The Kaplan-Meier plots of 66 hips with steroid-associated ONFH received HGF treatment. Plot A shows that the mean survival time of 15.95 years. Plot B shows that hips with ARCO stage IV (red) have poorer prognosis, as their survival probability is lower than those with ARCO stage 20 I to III (green, blue and purple).
As for the 28 patients who did not undergo THA, the most recent follow-up examination showed a We further analyzed the HHS of those five patients who had one of their severer affected hips replaced in our hospital. No significant difference was observed in terms of HHS-physical function index between these five patients and the 28 patients mentioned above. Nevertheless, lower HHS-pain index and total HHS were found in these five patients (P 0.05, see Fig. 3 ), which suggested patients with bilateral ONFH still experienced a considerable loss of hip function although they had already surgical replacement of the severer side of hips.
Radiographic evaluation (see Fig. 5&6 )
At the most recent follow-up visit, we observed that the collapse of the femoral head had occurred in 14 (26.41%) of 53 previously pre-collapse hips. Meanwhile, osteoarthritis (K-L grade 2 to 4) had occurred in 27 (50.94%) of 53 previously pre-collapse hips, and 11 (84.61%) in 13 previously collapsed hips.
Osteoarthritis
We used Kendall's Tau-b method to examine the relationship between degrees of severity with regards to hip osteoarthritis, pain, and physical function (see Fig. 4 ). However, we failed to observe significant correlations between degrees of osteoarthritis and degrees of HHS-pain index, degrees of osteoarthritis and degrees of walking function index, as well as degrees of HHS-pain index and degrees of walking function index.
We also observed four patients without osteoarthritis (K-L grade 0) complained of chronic moderate hip pain, and two patients with doubtful hip osteoarthritis (K-L grade 1) complained of chronic intense hip pain. These data indicated osteoarthritis could not fully explain the source of pain, and some other factors which might also be involved in causing pain in these patients. without severe depression of femoral head.
Discussion
HGF demonstrated a promising effect on the treatment of the steroid-associated ONFH among convalescent SARS patients 26, 27 , but the long-term outcome remained uncertain. This retrospective cohort study aimed to evaluate the long-term outcome of HGF therapy on these unique patients. The goal of hip-preserving treatments is not only to avoid or delay THA surgery but also to maintain or restore the physical function of the hip joint. HHS is an outcome measure frequently used for evaluation of the physical function among patients with hip joint disorders 29, 30 . We observed a mean HHS of 63.89±10.30 in 28 patients without THA at the end of the present study. Although the data suggest that HGF therapy only yields poor results (HHS<70), but our data are still comparable to previous relevant studies [31] [32] [33] [34] . Alendronate is one of the most commonly used pharmacological treatments for ONFH 35 . In 2005, an RCT study included 20 patients who received 25-week alendronate treatment, reported a mean HHS of 74.4±7.8 after a follow-up duration of two years 33 . However, the efficacy of alendronate for treating ONFH has been questioned by later studies 36, 37 . Core decompression is believed to be the most reliable operative treatment for pre-collapse ONFH 38 . Even so, an RCT study published in 2017 reported a mean HHS of 68±5 in 21 patients who had undergone core decompression surgery at three years follow-up visit 34 .
In the current study, we separate the original HHS into the pain index and the physical function index.
The latter evaluates diverse ability of daily living (ADL), including the need of walking aids, distance walked, limp, wearing shoes and socks, climbing stairs, public transportation, sitting, and range of motion. Moreover, we observed these 28 patients without THA had maintained 70% of the aforementioned ability of daily living after a mean follow-up duration of 14 years, by the rating method of HHS-physical function index.
ONFH can cause rapidly worsening hip osteoarthritis, which is believed to be the source of groin pain and reduced physical function. Although we observed high morbidity of osteoarthritis in the studied cohort, the severity of pain was not proportional to the severity of osteoarthritis. We recorded 4 patients without hip osteoarthritis complained of moderate groin pain, and two patients with doubtful hip osteoarthritis complained of intense groin pain. Since chronic pain is a complex of subjective sensory and emotional experience, and psychobehavioural problems are not uncommon among these special patients 39 , we daringly hypothesize this inexplicable groin pain can somewhat be ascribed to chronic pain sensitization or depression.
A significant limitation of our study is the lack of SARS patients with or without medical interventions as control. However, there is still no treatment-as-usual available, and it would not have been ethical to give placebo treatment as well. A similar study reported combined vasoactive pharmacotherapy could successfully prevent collapse, but their 14-year study only included four SARS patients 40 . On the other hand, few randomized clinical trials concerning ONFH can be followed-up for a long term. Published studies mostly reported their results after a follow-up duration of only two or three years 4, 34, 41 , but the previous study had reported that the interval between diagnosis and collapse could be over four years in 46% of cases 42 . In comparison to the natural collapse rate of 49% reported by a systematic review that included the most hips with ONFH 28 , our study observed a collapse rate of 26% based on prolonged follow-up data, supporting that HGF helps prevent the natural disease progression of ONFH.
To the best of our knowledge, this is the first study that addresses the longest-term outcomes of Chinese medicine therapy for steroid-associated ONFH. The results of this 14-year follow-up study support the role of HGF, a Spleen-invigorating Chinese herbal medication for the treatment of steroid-associated ONFH, for deferring the time for THA, preventing progression to femoral head collapse, maintaining the physical function. Despite our long-term observation supported high morbidity of hip osteoarthritis, patients experienced inexplicable groin pain that is not correlated to the severity of hip osteoarthritis. Nevertheless, HGF should be considered as an effective therapeutic option for steroid-associated ONFH.
